source
- Roche signs $2.5 billion deal with Hanmi for experimental obesity drug targeting muscle lossRoche's Genentech unit has agreed to acquire global rights (outside South Korea) to Hanmi's clinical-stage urocortin-2 analog, HM17321, as part of a deal valued up to $2.5 billion. The agreement i…
- Moderna and Merck report promising results from cancer vaccine amid early skepticismModerna and Merck say their experimental mRNA cancer vaccine has produced encouraging mid‑stage data, shifting the narrative from doubt to optimism. At a March 2023 leadership meeting, executives…